CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
77.12
1.06%
Market Trading Hours* (UTC) Opens on Thursday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.15
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

CVS Health Corp ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 76.31
Open* 76.2
1-Year Change* -13.77%
Day's Range* 76.2 - 77.22
52 wk Range 64.41-90.62
Average Volume (10 days) 16.43M
Average Volume (3 months) 186.78M
Market Cap 95.08B
P/E Ratio 11.15
Shares Outstanding 1.29B
Revenue 347.81B
EPS 6.63
Dividend (Yield %) 3.60043
Beta 0.50
Next Earnings Date Feb 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 20, 2024 76.31 -0.65 -0.84% 76.96 77.51 76.08
Feb 16, 2024 77.03 0.46 0.60% 76.57 77.40 76.27
Feb 15, 2024 76.53 -0.08 -0.10% 76.61 77.87 76.50
Feb 14, 2024 76.34 -0.20 -0.26% 76.54 77.49 75.98
Feb 13, 2024 76.54 -0.31 -0.40% 76.85 78.24 76.12
Feb 12, 2024 77.24 1.47 1.94% 75.77 77.96 75.53
Feb 9, 2024 76.26 1.44 1.92% 74.82 76.30 74.40
Feb 8, 2024 75.02 -0.54 -0.71% 75.56 75.80 74.50
Feb 7, 2024 76.01 0.90 1.20% 75.11 77.32 74.96
Feb 6, 2024 73.69 1.32 1.82% 72.37 74.11 72.35
Feb 5, 2024 72.38 -0.66 -0.90% 73.04 73.15 71.52
Feb 2, 2024 73.02 -0.71 -0.96% 73.73 74.22 72.96
Feb 1, 2024 73.86 -0.53 -0.71% 74.39 74.44 73.40
Jan 31, 2024 74.31 0.27 0.36% 74.04 74.93 73.74
Jan 30, 2024 73.81 -0.05 -0.07% 73.86 74.16 73.41
Jan 29, 2024 73.43 0.60 0.82% 72.83 73.58 72.78
Jan 26, 2024 72.95 0.78 1.08% 72.17 72.95 71.90
Jan 25, 2024 71.95 0.12 0.17% 71.83 72.32 70.11
Jan 24, 2024 74.13 -1.79 -2.36% 75.92 76.54 73.93
Jan 23, 2024 75.05 1.11 1.50% 73.94 75.05 73.86

CVS Health Events

Time (UTC) Country Event
Wednesday, May 1, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 CVS Health Corp Earnings Release
Q1 2024 CVS Health Corp Earnings Release

Forecast

-

Previous

-
Friday, May 17, 2024

Time (UTC)

12:00

Country

US

Event

CVS Health Corp Annual Shareholders Meeting
CVS Health Corp Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 322467 292111 268706 256776 194579
Revenue 322467 292111 268706 256776 194579
Cost of Revenue, Total 196892 175803 163981 158719 156447
Gross Profit 125575 116308 104725 98057 38132
Total Operating Expense 314721 279370 256235 244868 190558
Selling/General/Admin. Expenses, Total 745 523 461 396 21368
Unusual Expense (Income) 8336 2373 1503 559 6149
Other Operating Expenses, Total 108748 100671 90290 85194 6594
Operating Income 7746 12741 12471 11908 4021
Interest Income (Expense), Net Non-Operating -2287 -2503 -2907 -3035 -2619
Other, Net 169 182 206 124 4
Net Income Before Taxes 5628 10420 9770 8997 1406
Net Income After Taxes 4165 7898 7201 6631 -696
Minority Interest -16 12 -13 3 2
Net Income Before Extra. Items 4149 7910 7188 6634 -694
Total Extraordinary Items 0 0 -9 0 100
Net Income 4149 7910 7179 6634 -594
Total Adjustments to Net Income 0 0 -3
Income Available to Common Excl. Extra. Items 4149 7910 7188 6634 -697
Income Available to Common Incl. Extra. Items 4149 7910 7179 6634 -597
Diluted Net Income 4149 7910 7179 6634 -597
Diluted Weighted Average Shares 1323 1329 1314 1305 1044
Diluted EPS Excluding Extraordinary Items 3.13605 5.95184 5.47032 5.08352 -0.66762
Dividends per Share - Common Stock Primary Issue 2.2 2 2 2 2
Diluted Normalized EPS 7.79898 7.27044 6.31339 5.51501 3.16078
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 88921 85278 83846 81159 80636
Revenue 88921 85278 83846 81159 80636
Cost of Revenue, Total 53536 51455 51728 50365 49290
Gross Profit 35385 33823 32118 30794 31346
Total Operating Expense 85687 81832 80228 85090 75967
Selling/General/Admin. Expenses, Total
Unusual Expense (Income) 496 349 111 7700 0
Other Operating Expenses, Total 31655 30028 28389 27025 26677
Operating Income 3234 3446 3618 -3931 4669
Interest Income (Expense), Net Non-Operating -686 -589 -552 -566 -583
Other, Net 22 22 43 41 43
Net Income Before Taxes 2570 2879 3109 -4456 4129
Net Income After Taxes 1914 2142 2300 -3409 3039
Minority Interest -13 -6 2 -7 -10
Net Income Before Extra. Items 1901 2136 2302 -3416 3029
Net Income 1901 2136 2302 -3416 3029
Income Available to Common Excl. Extra. Items 1901 2136 2302 -3416 3029
Income Available to Common Incl. Extra. Items 1901 2136 2302 -3416 3029
Diluted Net Income 1901 2136 2302 -3416 3029
Diluted Weighted Average Shares 1287 1291 1320 1315 1321
Diluted EPS Excluding Extraordinary Items 1.47708 1.65453 1.74394 -2.59772 2.29296
Dividends per Share - Common Stock Primary Issue 0.82175 0.605 0.55 0.55 0.55
Diluted Normalized EPS 1.86131 1.89485 1.80615 1.20837 2.29296
Total Extraordinary Items 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 65682 60008 56369 50302 45243
Cash and Short Term Investments 15723 12525 10854 8056 6581
Cash & Equivalents 12945 9408 7854 5683 4059
Short Term Investments 2778 3117 3000 2373 2522
Total Receivables, Net 27276 24431 21742 19617 17631
Accounts Receivable - Trade, Net 8983 7932 7101 17236 17631
Total Inventory 19090 17760 18496 17516 16450
Other Current Assets, Total 3593 5292 5277 5113 4581
Total Assets 228275 232999 230715 222449 196456
Property/Plant/Equipment, Total - Net 30989 32018 33335 32904 11349
Property/Plant/Equipment, Total - Gross 52472 52672 52035 49794 26869
Accumulated Depreciation, Total -21483 -20654 -18700 -16890 -15520
Goodwill, Net 78150 79121 79552 79749 78678
Intangibles, Net 24754 29026 31142 33121 36524
Other Long Term Assets, Total 7604 9801 9505 9059 8930
Total Current Liabilities 69736 67807 62017 53303 44009
Accounts Payable 44667 38682 34869 30972 26437
Accrued Expenses 20352 19229 15810 13656 10711
Notes Payable/Short Term Debt 0 0 0 0 720
Current Port. of LT Debt/Capital Leases 1778 4205 5440 3781 1265
Total Liabilities 157260 157924 161326 158585 138231
Total Long Term Debt 50476 51971 59207 64699 71444
Long Term Debt 49070 50721 58157 63918 71444
Deferred Income Tax 3880 6270 6794 7294 7677
Minority Interest 300 306 312 306 318
Other Liabilities, Total 32868 31570 32996 32983 14783
Total Equity 71015 75075 69389 63864 58225
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 48193 47377 46513 45972 45440
Additional Paid-In Capital
Retained Earnings (Accumulated Deficit) 56145 54906 49640 45108 40911
Treasury Stock - Common -31858 -28173 -28178 -28235 -28228
Other Equity, Total 36 187 200 245 5
Total Liabilities & Shareholders’ Equity 228275 232999 230715 222449 196456
Total Common Shares Outstanding 1300 1322 1310 1302 1295
Long Term Investments 21096 23025 20812 17314 15732
Other Current Liabilities, Total 2939 5691 5898 4894 4876
Unrealized Gain (Loss) -1501 778 1214 774 97
Capital Lease Obligations 1406 1250 1050 781
Total Preferred Shares Outstanding 0 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 70143 67756 68706 65682 68341
Cash and Short Term Investments 16188 16887 17720 15723 19989
Cash & Equivalents 13043 13807 14618 12945 17197
Short Term Investments 3145 3080 3102 2778 2792
Total Receivables, Net 32927 29546 28331 27276 26317
Accounts Receivable - Trade, Net 10424 9949 9229 8983 8016
Total Inventory 17954 17291 18263 19090 18058
Other Current Assets, Total 3074 4032 4392 3593 3977
Total Assets 251306 250071 239330 228275 231212
Property/Plant/Equipment, Total - Net 30586 30704 30532 30989 30896
Goodwill, Net 91261 91260 84057 78150 78086
Intangibles, Net 29624 30118 26368 24754 25157
Long Term Investments 21667 22114 21612 21096 20565
Other Long Term Assets, Total 8025 8119 8055 7604 8167
Total Current Liabilities 81553 79206 75054 69736 72409
Accounts Payable 48921 45782 43469 44667 43437
Accrued Expenses 24145 24376 23058 20352 21036
Notes Payable/Short Term Debt 0 1000 0 0 0
Current Port. of LT Debt/Capital Leases 2132 1402 1778 1778 1363
Other Current Liabilities, Total 6355 6646 6749 2939 6573
Total Liabilities 176969 177345 167948 157260 160529
Total Long Term Debt 59782 61419 56450 50476 50848
Long Term Debt 59782 61419 56450 50476 50848
Deferred Income Tax 4250 4588 4095 3880 3508
Minority Interest 173 276 198 300 328
Other Liabilities, Total 31211 31856 32151 32868 33436
Total Equity 74337 72726 71382 71015 70683
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 48829 48649 48306 48193 48047
Retained Earnings (Accumulated Deficit) 60343 58868 57753 56145 54571
Treasury Stock - Common -33831 -33933 -33802 -31858 -30326
Unrealized Gain (Loss) -1434 -1113 -1049 -1501 -1813
Other Equity, Total 430 255 174 36 204
Total Liabilities & Shareholders’ Equity 251306 250071 239330 228275 231212
Total Common Shares Outstanding 1287 1282 1279 1300 1315
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Cash From Operating Activities 16177 18265 15865 12848 8865
Cash Receipts 313662 284219 264327 248393 186519
Cash Payments -189766 -165783 -158636 -149655 -148821
Cash Taxes Paid -4116 -3195 -2929 -2717 -2383
Cash Interest Paid -2239 -2469 -2904 -2954 -2803
Changes in Working Capital -101364 -94507 -83993 -80219 -23647
Cash From Investing Activities -5047 -5261 -5534 -3339 -43285
Capital Expenditures -2727 -2520 -2437 -2457 -2037
Other Investing Cash Flow Items, Total -2320 -2741 -3097 -882 -41248
Cash From Financing Activities -10516 -11356 -7696 -7654 36819
Financing Cash Flow Items -449 -13 337 59 350
Total Cash Dividends Paid -2907 -2625 -2624 -2603 -2038
Issuance (Retirement) of Stock, Net -2949 549 264 210 242
Issuance (Retirement) of Debt, Net -4211 -9267 -5673 -5320 38265
Foreign Exchange Effects -4
Net Change in Cash 614 1648 2635 1855 2395
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Cash From Operating Activities 7438 16177 18129 9006 3563
Cash Receipts 87798 313662 235395 151769 74192
Cash Payments -50223 -189766 -138785 -90887 -44365
Cash Taxes Paid -75 -4116 -3070 -1887 -96
Cash Interest Paid -773 -2239 -1936 -1150 -782
Changes in Working Capital -29289 -101364 -73475 -48839 -25386
Cash From Investing Activities -8514 -5047 -4928 -4123 -1993
Capital Expenditures -984 -2727 -2039 -1459 -1082
Other Investing Cash Flow Items, Total -7530 -2320 -2889 -2664 -911
Cash From Financing Activities 2726 -10516 -8329 -5111 -2650
Financing Cash Flow Items -162 -449 -456 -468 -211
Total Cash Dividends Paid -779 -2907 -2188 -1462 -722
Issuance (Retirement) of Stock, Net -1922 -2949 -1490 -1652 -1703
Issuance (Retirement) of Debt, Net 5589 -4211 -4195 -1529 -14
Net Change in Cash 1650 614 4872 -228 -1080
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.0377 116080051 404951 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.6675 59949540 -577905 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.3505 55877387 855269 2023-06-30 LOW
Capital World Investors Investment Advisor 2.3739 30490802 -2143168 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.816 23325287 363384 2023-06-30 LOW
Morgan Stanley Smith Barney LLC Investment Advisor 1.6524 21223161 292758 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 1.4302 18368906 6132147 2023-06-30 LOW
Dodge & Cox Investment Advisor/Hedge Fund 1.2476 16024422 3417573 2023-06-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.1909 15295808 1456938 2022-12-31 LOW
BofA Global Research (US) Research Firm 1.1233 14427290 -1221553 2023-06-30 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 0.9649 12393434 397285 2023-06-30 LOW
Invesco Advisers, Inc. Investment Advisor 0.9238 11865467 713725 2023-06-30 LOW
JP Morgan Asset Management Investment Advisor 0.8796 11297334 -5303256 2023-06-30 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.7704 9895356 402716 2023-06-30 LOW
Nordea Funds Oy Investment Advisor 0.7663 9841828 -610528 2023-06-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.7558 9707504 -407312 2023-06-30 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.7265 9331654 745498 2023-06-30 LOW
Two Sigma Investments, LP Hedge Fund 0.7218 9270389 563767 2023-06-30 HIGH
Goldman Sachs Asset Management, L.P. Investment Advisor 0.6851 8799049 -640765 2023-06-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.6413 8237038 -426578 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

CVS Company profile

CVS Health (CVS) is an American health service provider headquartered in Woonsocket, Rhode Island. 

In 1963, brothers Stanley and Sidney Goldstein, and Ralph Hoagland founded the company in Lowell, Massachusetts. The first CVS store sold health and beauty products. CVS stands for Consumer Value Stores.

CVS Health has four business segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other.

The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, MedicareAdvantage and health information. The segment serves around 35 million customers, including employer groups, individuals, college students, part-time and hourly workers, health care providers, government-sponsored plans, labour groups and expatriates.

The Pharmacy Services segment provides pharmacy benefit management (PBM) solutions, including, plan design offerings and administration, formulary management, retail pharmacy network management services, mail order pharmacy, clinical services and disease management services. The segment’s customers include employers, insurance companies, unions, government employee groups, health plans, plans offered on insurance exchanges and other sponsors of health benefit plans.

The Retail/LTC segment sells prescription drugs, health and wellness products, and general merchandise. It also provides health care services through its MinuteClinic walk-in medical clinics, medical diagnostic testing, and administers vaccinations for illnesses such as influenza and Covid-19. 

Long-term care pharmacy operations are also part of the segment. They distribute prescription pharmaceuticals as well as provide pharmacy consulting and other ancillary services to care homes and other care settings.

As of 31 December 2021, the Retail/LTC segment operated more than 9,900 locations, nearly 1,200 MinuteClinic locations, online services, LTC pharmacies and on-site pharmacies. CVS Health announced in November 2021 that it plans to close 900 stores in the next three years as part of its strategy to overhaul its retail business. The closures will start in spring 2022.

The company dispensed about 26.4% of all retail pharmacy prescriptions in the US in 2021. 

The Corporate/Other segment provides management and administrative expenses to support the Company’s overall operations. It also offers products for which the company no longer solicits or accepts new customers such as large case pensions and long-term care insurance products.

The company’s shares are traded on the New York Stock Exchange under the ticker symbol CVS.

Industry: Healthcare Facilities & Services (NEC)

1 Cvs Dr
WOONSOCKET
RHODE ISLAND 02895-6146
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

Oil - Crude

78.01 Price
+1.030% 1D Chg, %
Long position overnight fee 0.0066%
Short position overnight fee -0.0285%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

17,594.10 Price
+0.450% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 1.8

XRP/USD

0.55 Price
-3.210% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Gold

2,025.11 Price
+0.020% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading